Novartis AG 2019 SR
The report highlights Novartis' progress in ESG areas, focusing on ethical standards, access to healthcare, global health, and corporate citizenship. Key achievements include reaching 16 million patients through access programs and delivering over 900 million treatment courses of Coartem for malaria. The company launched the Novartis Africa sickle cell disease program in Ghana and committed to becoming carbon neutral in its operations by 2025. Additionally, Novartis achieved a 99/100 score for clinical trial transparency and reported a 44% representation of women in management.
Company: Novartis AG
Sector: Manufacturing
Country: Switzerland
Year: 2019
Type: SR
Pages: 70
Back to company
Novartis AG
ESG Report
The report highlights Novartis' progress in ESG areas, focusing on ethical standards, access to healthcare, global health, and corporate citizenship. Key achievements include reaching 16 million patients through access programs and delivering over 900 million treatment courses of Coartem for malaria. The company launched the Novartis Africa sickle cell disease program in Ghana and committed to becoming carbon neutral in its operations by 2025. Additionally, Novartis achieved a 99/100 score for clinical trial transparency and reported a 44% representation of women in management.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Jan 1, 2019 - Dec 31, 2019
Fiscal Year
2019
Published
Jan 28, 2020
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Sustainable Development Goals
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Women on Board
Women in Management
Net Zero Target
Employees